Abstract 724
Background
Screening and management of distress are essential. The Distress thermometer (DT) is a common screening tool. However, it’s cutoff score and the accuracy properties such as sensitivity and specificity is still unclear in Chinese cancer patients.
Methods
In this cross-sectional study, DT was compared against the Hospital Anxiety and Depression Scale (HADS) in 784 heterogeneous cancer inpatients. The HADS cutoff score ≥15, ≥6, and ≥9 were used to define distress, anxiety, and depression respectively. Receiver operating characteristic (ROC) analysis was applied to determine the discriminative accuracy of DT against each scale.
Results
When DT was compared against HADS-T, ROC showed an excellent area under the curve (AUC) of 0.903. The optimal cutoff score of 4 yielded sensitivity (SE)=89.3%, specificity (SP)=85.8%, positive predictive value (PPV)=89.9%, negative predictive value (NPV)=85.0%, screening utility (UI-)=.729, and case-finding utility (UI+)=.802. Furthermore, compared With HADS subscales, AUC=0.801 with a cutoff score 3 on DT optimally detected SE = 80.7%, SP = 64.5% PPV=89.4%, NPV=47.3%, UI-=.369, andUI + =.721 for anxiety and AUC=0.802 with a cutoff score of 4 on DT optimally detected SE = 88.3%, SP = 65.3%, PPV=66.4%, NPV=87.8%, UI-=.573 and UI + =.586 for depression respectively. DT Scores were moderately correlated with HADS-Total, HADS-Anxiety, andHADS-Depression. Female gender, low education level, advanced cancer stage, no exercise habit, suicidal ideation and months since diagnosis more than 12 were found to be associated with distress.
Conclusions
For Chinese patients with cancer, DT is an efficacious screening and case finding a tool for distress. Among the subscales, DT performed well in both screening and case finding for depression, however, although the case finding was good it carried a poor screening ability for anxiety.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract